ClinicalTrials.gg
CompletedNCT04109976Updated Nov 30, 2023Results posted

A Study to Evaluate the Safe and Effective Use of the Prefilled Safety Syringe or the Auto-injector for the Subcutaneous Self-injection of Bimekizumab Solution by Subjects With Active Psoriatic Arthritis

A Phase 3 interventional study of Bimekizumab in Psoriatic Arthritis, sponsored by UCB Biopharma SRL. Completed at 47 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-11-30.

Sponsored by UCB Biopharma SRL (part of UCB S.A.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
214
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies testing bimekizumab in Arthritis, Psoriatic — 2 open to participants now, 3 under way, 1 of them phase 3. bimekizumab · Arthritis, Psoriatic.

Enrollment
7th of 14
214 · median 210
Started
2019
with 3 others
Phase 3
8 of 14
none open now
Registered
9th of 14
by date
Lead sponsor
10 of 14
UCB Biopharma SRL

Among the 14 studies testing bimekizumab in Arthritis, Psoriatic, this one is the 7th largest by enrollment, is one of 4 that started in 2019, is one of 8 in phase 3, and was the 9th registered.

Arthritis, Psoriatic

601 studies on the registry are indexed under Arthritis, Psoriatic; 129 are open to participants now.

Browse Arthritis, Psoriatic studies →

Open to participants now

2 of the 14 studies testing bimekizumab in Arthritis, Psoriatic are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About bimekizumab

bimekizumab: first FDA approval 2023 (BIMZELX), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 88 Arthritis, Psoriatic studies recruiting now, 53 (60%) set no upper age limit and 26 (30%) stop at 75 or younger; 12 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing bimekizumab in Arthritis, Psoriatic, or all of them as a file.
02

Study summary

The purpose of the study is to evaluate for each self-injecting device presentation the ability of subjects with psoriatic arthritis (PsA) to safely and effectively self-inject bimekizumab at study start and 4 weeks after training in self-injection technique using the bimekizumab safety syringe (SS) or the bimekizumab auto-injector (AI).

03

Conditions studied

  • Psoriatic Arthritis

Browse trials for

Keywords

  • Psoriatic Arthritis
  • PsA
  • Auto-Injector
  • Bimekizumab
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject fulfills all inclusion criteria for the PA0012 [NCT04009499] study
  • Subject is considered reliable and capable of adhering to the DV0004 protocol (eg, able to understand and complete questionnaires, able to use self-injecting device presentations according to the instructions for use (IFU), and able to adhere to the visit schedule) according to the judgment of the Investigator
  • Subject is willing to self-inject

Exclusion criteria

Exclusion Criteria:

-Subjects are not permitted to enroll in DV0004 if any of the PA0012 [NCT04009499] study exclusion criteria are met

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
214 participants (actual)

Study arms

  • Experimental
    Bimekizumab-SS

    Study participants randomized to this arm will receive assigned bimekizumab dose regimen using the prefilled safety syringe (SS).

    Drug: Bimekizumab

  • Experimental
    Bimekizumab-AI

    Study participants randomized to this arm will receive assigned bimekizumab dose regimen using the auto-injector (AI).

    Drug: Bimekizumab

Interventions

  • Study participants will receive bimekizumab at pre-specified time points.

    Also known as: UCB4940, BKZ

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Able to Self-administer Safe and Effective Injections Using the Bimekizumab Safety Syringe (BKZ-SS) or the Bimekizumab Auto-injector (BKZ-AI) at Week 4

    Safe and effective self-injection was evaluated by the study personnel and was defined as: - Complete dose delivery: Participant self-injected the complete dose of bimekizumab as confirmed by a visual inspection of the bimekizumab-safety syringe (SS) or the bimekizumab-auto-injector (AI) which shows that the investigational medicinal product (IMP) was delivered completely (ie, container is empty), and - No Adverse Device Effects (ADEs) that would preclude continued use of the device for self-injection (ie, no serious ADEs (SADEs) and/or ADEs leading to withdrawal).

    Time frame: Week 4

Secondary outcomes

  1. Percentage of Participants Able to Self-administer Safe and Effective Injections Using the Bimekizumab Safety Syringe (BKZ-SS) or the Bimekizumab Auto-injector (BKZ-AI) at Baseline

    Safe and effective self-injection was evaluated by the study personnel and was defined as: - Complete dose delivery: Participant self-injected the complete dose of bimekizumab as confirmed by a visual inspection of the bimekizumab-SS or the bimekizumab-AI which shows that the IMP is delivered completely (ie, container is empty), and - No ADEs that would preclude continued use of the device for self-injection (ie, no SADEs and/or ADEs leading to withdrawal).

    Time frame: Baseline

07

Results

Posted Nov 30, 2023

Participant flow

The study started to enroll study participants in Aug 2019 and concluded in Nov 2020. This study is a substudy to PA0012 (NCT04009499).

Participant flow — Overall Study
MilestoneBKZ-SS-1mL 160 mg Q4WBKZ-AI-1mL 160 mg Q4W
Started107107
Completed106107
Not completed10
Withdrew: Withdrawal by subject10

Outcome measures

PrimaryPercentage of Participants Able to Self-administer Safe and Effective Injections Using the Bimekizumab Safety Syringe (BKZ-SS) or the Bimekizumab Auto-injector (BKZ-AI) at Week 4

Safe and effective self-injection was evaluated by the study personnel and was defined as: - Complete dose delivery: Participant self-injected the complete dose of bimekizumab as confirmed by a visual inspection of the bimekizumab-safety syringe (SS) or the bimekizumab-auto-injector (AI) which shows that the investigational medicinal product (IMP) was delivered completely (ie, container is empty), and - No Adverse Device Effects (ADEs) that would preclude continued use of the device for self-injection (ie, no serious ADEs (SADEs) and/or ADEs leading to withdrawal).

Time frame:
Week 4
Reported as:
Number · percentage of participants
Percentage of Participants Able to Self-administer Safe and Effective Injections Using the Bimekizumab Safety Syringe (BKZ-SS) or the Bimekizumab Auto-injector (BKZ-AI) at Week 4
percentage of participantsBKZ-SS-1mL 160 mg Q4WBKZ-AI-1mL 160 mg Q4W
Percentage of Participants Able to Self-administer Safe and Effective Injections Using the Bimekizumab Safety Syringe (BKZ-SS) or the Bimekizumab Auto-injector (BKZ-AI) at Week 4100 (97.2 to 100)100 (97.2 to 100)
SecondaryPercentage of Participants Able to Self-administer Safe and Effective Injections Using the Bimekizumab Safety Syringe (BKZ-SS) or the Bimekizumab Auto-injector (BKZ-AI) at Baseline

Safe and effective self-injection was evaluated by the study personnel and was defined as: - Complete dose delivery: Participant self-injected the complete dose of bimekizumab as confirmed by a visual inspection of the bimekizumab-SS or the bimekizumab-AI which shows that the IMP is delivered completely (ie, container is empty), and - No ADEs that would preclude continued use of the device for self-injection (ie, no SADEs and/or ADEs leading to withdrawal).

Time frame:
Baseline
Reported as:
Number · percentage of participants
Percentage of Participants Able to Self-administer Safe and Effective Injections Using the Bimekizumab Safety Syringe (BKZ-SS) or the Bimekizumab Auto-injector (BKZ-AI) at Baseline
percentage of participantsBKZ-SS-1mL 160 mg Q4WBKZ-AI-1mL 160 mg Q4W
Percentage of Participants Able to Self-administer Safe and Effective Injections Using the Bimekizumab Safety Syringe (BKZ-SS) or the Bimekizumab Auto-injector (BKZ-AI) at Baseline100 (97.2 to 100)100 (97.2 to 100)

Adverse events

Collected over From Baseline up to Week 5. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
BKZ-SS-1mL 160 mg Q4W0/107 (0%)0/107 (0%)0/107 (0%)
BKZ-AI-1mL 160 mg Q4W0/107 (0%)0/107 (0%)0/107 (0%)

Baseline characteristics

Baseline Characteristics refer to the Safety Set (SS) consisted of all study participants who received at least 1 dose of bimekizumab by the indicated self-injection investigational device presentation (bimekizumab-SS-1mL \[SS-s\] and bimekizumab-AI-1mL \[SS-a\]).

Age, Categorical
Age, Categorical(Participants)BKZ-SS-1mL 160 mg Q4WBKZ-AI-1mL 160 mg Q4WTotal
<=18 years000
Between 18 and 65 years9491185
>=65 years131629
Age, Continuous
Age, Continuous(years)BKZ-SS-1mL 160 mg Q4WBKZ-AI-1mL 160 mg Q4WTotal
Mean48.3 ± 13.251.5 ± 11.949.9 ± 12.6
Sex: Female, Male
Sex: Female, Male(Participants)BKZ-SS-1mL 160 mg Q4WBKZ-AI-1mL 160 mg Q4WTotal
Female5454108
Male5353106
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)BKZ-SS-1mL 160 mg Q4WBKZ-AI-1mL 160 mg Q4WTotal
White106107213
Other/Mixed101
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)BKZ-SS-1mL 160 mg Q4WBKZ-AI-1mL 160 mg Q4WTotal
Not Hispanic or Latino106107213
Hispanic or Latino101
08

Study locations

47 sites
  • Dv0004 50024
    Boise, Idaho 83702, United States
  • Dv0004 50028
    Lexington, Kentucky 40504, United States
  • Dv0004 50023
    Baton Rouge, Louisiana 70836, United States
  • Dv0004 50015
    Hagerstown, Maryland 21742, United States
  • Dv0004 50026
    Wheaton, Maryland 20902, United States
  • Dv0004 50019
    Lansing, Michigan 48910, United States
  • Dv0004 50016
    Saint Louis, Missouri 63141, United States
  • Dv0004 50005
    Freehold, New Jersey 07728, United States
  • Dv0004 50029
    Albuquerque, New Mexico 87102, United States
  • Dv0004 50010
    Brooklyn, New York 11201, United States
  • Dv0004 50125
    Charlotte, North Carolina 28210, United States
  • Dv0004 50031
    Salisbury, North Carolina 28144, United States
  • Dv0004 50040
    Dayton, Ohio 45417, United States
  • Dv0004 50020
    Duncansville, Pennsylvania 16635, United States
  • Dv0004 50006
    Wyomissing, Pennsylvania 19610, United States
  • Dv0004 50008
    Johnston, Rhode Island 02919, United States
  • Dv0004 50001
    Jackson, Tennessee 38305, United States
  • Dv0004 50036
    Mesquite, Texas 75150, United States
  • Dv0004 50009
    Waco, Texas 76710, United States
  • Dv0004 50050
    Beckley, West Virginia 25801, United States
  • Dv0004 40061
    Brno, Czechia
  • Dv0004 40009
    Pardubice, Czechia
  • Dv0004 40066
    Praha 2, Czechia
  • Dv0004 40063
    Praha 5, Czechia
  • Dv0004 40010
    Uherské Hradiště, Czechia
  • Dv0004 40012
    Zlín, Czechia
  • Dv0004 40029
    Hamburg, Germany
  • Dv0004 40079
    Szentes, Hungary
  • Dv0004 40038
    Elbląg, Poland
  • Dv0004 40088
    Elbląg, Poland
  • Dv0004 40096
    Gdynia, Poland
  • Dv0004 40042
    Kraków, Poland
  • Dv0004 40092
    Kraków, Poland
  • Dv0004 40037
    Lublin, Poland
  • Dv0004 40091
    Nowa Sól, Poland
  • Dv0004 40044
    Poznań, Poland
  • Dv0004 40118
    Toruń, Poland
  • Dv0004 40041
    Warsaw, Poland
  • Dv0004 40097
    Warsaw, Poland
  • Dv0004 40098
    Warszawa, Poland
  • Dv0004 40039
    Wrocław, Poland
  • Dv0004 40043
    Wrocław, Poland
  • Dv0004 20005
    Moscow, Russian Federation
  • Dv0004 20013
    Petrozavodsk, Russian Federation
  • Dv0004 20004
    Saint Petersburg, Russian Federation
  • Dv0004 20014
    Ulyanovsk, Russian Federation
  • Dv0004 20015
    Yaroslavl, Russian Federation
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Data from this study may be requested by qualified researchers six months after product approval in the US and/or Europe, or global development is discontinued, and 18 months after trial completion. Investigators may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.clinicalstudydatarequest.com and a signed data sharing agreement will need to be executed. All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal. This plan may change if a determination is made that the data cannot be adequately anonymized.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data from this study may be requested by qualified researchers six months after product approval in the US and/or Europe or global development is discontinued, and 18 months after trial completion.

Access criteria: Qualified researchers may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.clinicalstudydatarequest.com and a signed data sharing agreement will need to be executed. All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal.

Data sharing details ↗ · clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2019 to primary completion in Nov 2020, 14 months.

Results were first posted in Nov 2023, 3 years after primary completion. A results delay was requested in Nov 2021.

Of 68 industry-sponsored phase 3 interventional studies under Arthritis, Psoriatic, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 39. This study's 14 months is below that.

Counting every sponsor, half of 74 studies reached it within 28 months; a quarter within 19 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 27, 2019
First posted
Oct 1, 2019
StartActual
Aug 13, 2019
Primary completionActual
Nov 5, 2020
CompletionActual
Nov 13, 2020
Results delay requested
Nov 4, 2021
Results first posted
Nov 30, 2023
Last update
Nov 30, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 30, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04109976
Lead sponsor
UCB Biopharma SRL
Responsible party
Sponsor
First posted
Oct 1, 2019
Start date
Aug 13, 2019
Primary completion
Nov 5, 2020
Completion
Nov 13, 2020
Results posted
Nov 30, 2023
Last update
Nov 30, 2023

Study contacts

UCB Cares
study director · 001 844 599 2273 (UCB)

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bimekizumab

Start the discussion